ADC Therapeutics SA
ADCT
$1.29
-$0.01-0.77%
NYSE
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -7.69% | -9.57% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -7.69% | -9.57% | |||
| Cost of Revenue | -16.08% | 33.48% | |||
| Gross Profit | 82.32% | -148.38% | |||
| SG&A Expenses | -1.46% | 5.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.91% | 18.07% | |||
| Operating Income | 9.92% | -57.95% | |||
| Income Before Tax | 49.75% | -383.90% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 49.75% | -414.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 49.75% | -414.40% | |||
| EBIT | 9.92% | -57.95% | |||
| EBITDA | 9.99% | -56.85% | |||
| EPS Basic | 58.77% | -508.69% | |||
| Normalized Basic EPS | 65.43% | -698.03% | |||
| EPS Diluted | 58.77% | -508.69% | |||
| Normalized Diluted EPS | 65.43% | -698.03% | |||
| Average Basic Shares Outstanding | 21.90% | -15.39% | |||
| Average Diluted Shares Outstanding | 21.90% | -15.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||